title: Insulin resistance in adipocytes after downregulation of Gi subtypes.
abstract: To determine whether downregulation of Gi proteins is associated with insulin resistance, we incubated isolated adipocytes with N6-(2-phenylisopropyl)adenosine (PIA; an A1-adenosine receptor agonist; 300 nM), prostaglandin E1 (PGE1; 3 microM), or nicotinic acid (1 mM) for 4 days in primary culture. The cells were washed, and the rate of glucose transport (2-deoxy-[3H]glucose uptake) was measured after incubation with various concentrations of insulin for 45 min. Both PIA and PGE1 (which downregulate Gi) decreased the maximal responsiveness of the cells to insulin by approximately 30% and caused a rightward shift in the dose-response curve. By contrast, nicotinic acid (which does not downregulate Gi) did not alter the insulin sensitivity of the cells. Prolonged treatment of adipocytes with either PIA or PGE1 (but not nicotinic acid) rendered the cells completely resistant to the antilipolytic effect of insulin. The ability of insulin to stimulate autophosphorylation of the beta-subunit of the insulin receptor was decreased by approximately 30% in PIA-treated cells, and the dose-response curve was shifted to the right. Similarly, the ability of the receptor to phosphorylate poly(Glu4-Tyr1) was decreased by approximately 35%. This decrease in tyrosine kinase activity of the receptor may account for the decrease in insulin sensitivity of glucose transport but cannot account for the complete loss of antilipolysis. The findings suggest both a direct and indirect involvement of Gi proteins in insulin action.
authors.affiliation: Department of Internal Medicine, University of Texas Medical Branch, Galveston 77555, USA.
authors.forename: A
authors.initials: A
authors.lastname: Green
authors.forename: D J
authors.initials: DJ
authors.lastname: Walters
authors.forename: S E
authors.initials: SE
authors.lastname: Belt
mesh_terms: D017667:Adipocytes / Q000187:drug effects / Q000502:physiology*; D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D019204:GTP-Binding Proteins / Q000378:metabolism*; D006861:Hydrogen Peroxide / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism / Q000494:pharmacology; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D009525:Niacin / Q000494:pharmacology; D010455:Peptides / Q000378:metabolism; D010660:Phenylisopropyladenosine / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D011972:Receptor, Insulin / Q000187:drug effects / Q000378:metabolism; D014638:Vanadates / Q000494:pharmacology
chemical_list: D007328:Insulin; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D009525:Niacin; D010660:Phenylisopropyladenosine; C027606:L-glutamic acid-L-tyrosine copolymer; D014638:Vanadates; D006861:Hydrogen Peroxide; D011972:Receptor, Insulin; D019204:GTP-Binding Proteins; D000527:Alprostadil